Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. High Carriage Rates of Multidrug-Resistant Gram-Negative Bacteria in Neonatal Intensive Care Units From Ghana

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Extrapulmonary Tuberculosis in Denmark From 2009 to 2014; Characteristics and Predictors for Treatment Outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • EuroSIDA study
Vis graf over relationer

Background: The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) in HIV-positive persons remains unclear.

Methods: Poisson regression was used to compare incidence rates of DM (blood glucose >11.1 mmol/L, HbA1C >6.5% or >48 mmol/mol, starting antidiabetic medicine or physician reported date of DM onset) between current HIV/HCV groups (anti-HCV-negative, spontaneously cleared HCV, chronic untreated HCV, successfully treated HCV, HCV-RNA-positive after HCV treatment).

Results: A total of 16 099 persons were included; at baseline 10 091 (62.7%) were HCV-Ab-negative, 722 (4.5%) were spontaneous clearers, 3614 (22.4%) were chronically infected, 912 (5.7%) had been successfully treated, and 760 (4.7%) were HCV-RNA-positive after treatment. During 136 084 person-years of follow-up (PYFU; median [interquartile range], 6.9 [3.6-13.2]), 1108 (6.9%) developed DM (crude incidence rate, 8.1/1000 PYFU; 95% CI, 7.7-8.6). After adjustment, there was no difference between the 5 HCV strata in incidence of DM (global P = .33). Hypertension (22.2%; 95% CI, 17.5%-26.2%) and body mass index >25 (22.0%; 95% CI, 10.4%-29.7%) had the largest population-attributable fractions for DM.

Conclusions: HCV coinfection and HCV cure were not associated with DM in this large study. The biggest modifiable risk factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.

OriginalsprogEngelsk
TidsskriftOpen Forum Infectious Diseases
Vol/bind7
Udgave nummer12
Sider (fra-til)ofaa470
ISSN2328-8957
DOI
StatusUdgivet - dec. 2020

Bibliografisk note

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

ID: 61701587